Evidence map›Paper›PMID 29312597›Full record

ArticleOncotarget2017

Targeting of CD122 enhances antitumor immunity by altering the tumor immune environment.

Daniel O Villarreal, Michael J Allegrezza, Melissa A Smith, Diana Chin, Leopoldo L Luistro, Linda A Snyder

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Circulating CD8BMC cancer · 2022
    Article
  4. Harnessing CD8Cells · 2021
    Review
  5. Evolutionary genetic algorithm identifiesNAR genomics and bioinformatics · 2021
    Article
  6. Galectin-1 fosters an immunosuppressive microenvironment in colorectal cancer by reprogramming CD8Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  7. Article
  8. Intratumoral HLA-DRFrontiers in oncology · 2020
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Daniel O VillarrealOncology Discovery, Janssen R&D, Spring House, PA 19477.
Michael J AllegrezzaOncology Discovery, Janssen R&D, Spring House, PA 19477.
Melissa A SmithOncology Discovery, Janssen R&D, Spring House, PA 19477.
Diana ChinOncology Discovery, Janssen R&D, Spring House, PA 19477.
Leopoldo L LuistroOncology Discovery, Janssen R&D, Spring House, PA 19477.
Linda A SnyderOncology Discovery, Janssen R&D, Spring House, PA 19477.
Janssen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mounting evidence demonstrates that CD8

Indexed as

CD122CD8 T cellsGITRimmunotherapyvaccines

Identifiers

PMID29312597
PMCPMC5752510
OpenAlexW2770749654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.